Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.

Leukemia · 2025 · PMC11879867 · PMID 39856223

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

pre-treatment in patient samples revealed upregulation of KRAS signaling, MYC targets, and inflammatory response but did not reach statistical significance (Supplementary Fig. 5F ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.